Emmaus Life Sciences Reports Quarterly Financial Results
LMP Capital and Income Fund Inc (NYSE: SCD) (the “Fund”) Announces Portfolio Management Team Update
Galmed Announces a Collaboration Agreement with Tel Aviv University to Evaluate its SCD1 inhibitor, Aramchol, as a Targeted Therapy for Metastatic Brain Cancers
Allspring Global Investments Holdings LLC Makes New Investment in LMP Capital and Income Fund Inc. $SCD
Galmed Announces the Breakthrough Development of a Brain Penetrating New Formulation of its SCD1 inhibitor, Aramchol
SCD: Unique CEF Could Be Well-Positioned To Outperform In The Current Environment
Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD) in The New England Journal of Medicine
SeaStar Medical Showcases New Positive Data from the QUELIMMUNE SAVE Registry and an Analysis of the Unique Immunomodulatory Mechanism of the SCD Therapy at AKI & CRRT 2026
Scandium Canada annonce l'augmentation de son placement privé par voie de prise ferme d'unités en vertu de la dispense pour financement de l'émetteur coté à 15 millions de dollars
Scandium Canada Announces $10 Million Bought Deal Life Offering of Units
10 Best CEFs This Month: Average Yield Of 9.7% (February 2026)
SeaStar Medical Announces Publication in Pediatric Nephrology of Positive Real-World Experience for QUELIMMUNE™ (SCD-PED) Therapy in Pediatric Acute Kidney Injury (AKI)
SCD: A Reasonable Fund For Income Investors
SeaStar Medical Announces 2026 Milestones
LMP Capital and Income Fund Inc. (SCD or “the Fund”; CUSIP: 50208A102) Announces Notification of Sources of Distributions
Absolute Investment Advisers LLC Buys Shares of 173,370 LMP Capital and Income Fund Inc. $SCD
Chapin Davis Inc. Sells 47,484 Shares of LMP Capital and Income Fund Inc. $SCD
LMP Capital and Income Fund Inc. (SCD or “the Fund”; CUSIP: 50208A102) Announces Notification of Sources of Distributions
10 Best CEFs This Month: Average Yield Of 9.5% (November 2025)
SCD: Sustainable Dividends Despite Inconsistent Earnings
LMP Capital and Income Fund Inc. (SCD or “the Fund”; CUSIP: 50208A102) Announces Notification of Sources of Distributions
10 Best CEFs This Month: Average Yield Of 9% Plus (October 2025)
Beam Therapeutics: SCD Catalysts Have Untapped Upside Potential
LMP Capital and Income Fund Inc. (SCD or “the Fund”; CUSIP: 50208A102) Announces Notification of Sources of Distributions
Scandium Canada updates on its proprietary Aluminum-Scandium Alloys
3 High Yield Dividends To Buy As Stocks Hit All-Time Highs
SCD: An Excellent Hybrid Fund For Income Investors, 9% Plus Yield
10 Best CEFs This Month: Average Yield Of Nearly 9% (August 2025)
SeaStar Medical Reaches New Enrollment Milestone in NEUTRALIZE-AKI Pivotal Trial of SCD Therapy for Adult Patients with Acute Kidney Injury (AKI)
5 Best CEFs This Month For Yields Up To 13% (July 2025)
LMP Capital and Income Fund Inc. Announces Final Results of Transferable Rights Offering
LMP Capital and Income Fund Inc. Announces Preliminary Results of Transferable Rights Offering
SCD Yields 9.27% After A 6% Distribution Bump
LMP Capital and Income Fund Inc. (SCD or “the Fund”; CUSIP: 50208A102) Announces Notification of Sources of Distributions
CEF Insights: Equity And Income In Focus: The SCD Approach
Firefly Neuroscience Researchers Uncover Powerful New Way of Objectively Measuring SCD, MCI, and Dementia in Alzheimer's Patients
Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress
AREVA Institute and SeaStar Medical Announce DoD Award of Prestigious Military Grant to AREVA Institute to Evaluate SeaStar Medical's SCD Therapy to Advance Breakthrough Burn and Sepsis Research
LMP Capital and Income Fund Inc. Authorizes 1-For-3 Rights Offering
SCD: This Hybrid Tech/Energy CEF Raised The Distribution, Now Has A Big Discount
LMP Capital and Income Fund Inc. Announces Results of Annual Meeting of Stockholders
Galmed Unveils Novel Pharmacodynamic Blood Markers for Aramchol, the Most Clinically Advanced SCD1 Inhibitor
Galmed Announces Positive Part 1 Results from the AM-001 Study of Aramchol Meglumine, an Enhanced Formulation of the Most Clinically Advanced SCD1 Inhibitor
FDA Grants SeaStar Medical Two New Breakthrough Device Designations for SCD Therapy to Treat Systemic Inflammatory Response in Adult and Pediatric Patients Undergoing Cardiac Surgery
3 Schwab ETFs to Buy With the VIX On the Rise
SCD: Continuing To Perform Well As Discount Narrows Further
5 Best CEFs This Month For Nearly 10% Yield (January 2025)
SCD: Monthly Paying CEF With Energy And Tech Exposure
Orna Therapeutics Establishes Strategic Collaboration with Vertex Pharmaceuticals to Develop Next Generation Approaches for Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)
LMP Capital and Income Fund Inc. (SCD or “the Fund”; CUSIP: 50208A102) Announces Notification of Sources of Distributions